Advanced cancer therapeutics are witnessing unprecedented innovation through bispecific antibody technology, particularly in treating non-small cell lung cancer. These sophisticated dual-targeting agents represent a paradigm shift from conventional monotherapy approaches, offering enhanced precision and efficacy. The therapeutic landscape continues evolving as researchers develop novel strategies to overcome treatment resistance and improve patient outcomes in one… Read.